journal article·2021-08-01Open access

Cold atmospheric plasma: A non-negligible strategy for viral RNA inactivation to prevent SARS-CoV-2 environmental transmission

Tao Jin, Yong Xu, Chenwei Dai, Xiuhong Zhou, Qinghua Xu, Zhengwei Wu

AIP Advances· Volume 11· Issue 8

Abstract

Cold atmospheric plasma (CAP), regarded as a powerful physics technology, displays antimicrobial, antitumor, and even antiviral properties, but the underlying mechanism is rarely studied. In this study, four CAP exposure doses (30, 60, 120, and 240 s) were applied to inactivate a severe acute respiratory syndrome coronavirus 2 like pseudovirus on a stainless steel disk, which comprised spike protein on its membrane and can express a green fluorescent protein. In order to unravel the potential effects of CAP irradiation on pseudovirus, infection assay, optical emission spectra analysis, transmission electron microscopy (TEM), sodium dodecyl sulfate polyacrylamide gel electrophoresis, ELISA, and qPCR experiments were carried out. As a result, our study indicated that CAP irradiation can significantly decrease the infectivity of pseudovirus in a dose dependent manner through destroying the cell membrane and further damaging viral RNA, with the molecular weight and conformation of spike receptor binding domain protein unchanged.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Infection Control and Ventilation · Plasma Applications and Diagnostics · COVID-19 impact on air quality

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Nuclear Science and Technology, University of Science and Technology of China 1 , Hefei, China

Anhui Academy of Medical Sciences 2 , Hefei, China

Key Laboratory of Geospace Environment, Chinese Academy of Sciences 3 , Hefei, China

Funding

The Key R&D Plan of Anhui Province

References (63)

Show source-provided references
1. COVID-19 (novel coronavirus 2019)—Recent trends10.26355/eurrev_202002_20378 ↗
2. Pandemic number five—Latest insights into the COVID-19 crisis10.1016/j.bj.2020.08.008 ↗
3. Coronavirus pandemic: Treatment and future prevention10.2217/fmb-2020-0174 ↗
4. An overview of current knowledge of deadly CoVs and their interface with innate immunity10.3390/v13040560 ↗
5. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review10.1002/ddr.21709 ↗
6. Growth, detection, quantification, and inactivation of SARS-CoV-210.1016/j.virol.2020.05.015 ↗
7. Possible impact of plasma oxidation on the structure of the C-terminal domain of SARS-CoV-2 spike protein: A computational study10.35848/1882-0786/abd717 ↗
8. Developmental status of the potential vaccines for the mitigation of the COVID-19 pandemic and a focus on the effectiveness of the Pfizer-BioNTech and Moderna mRNA vaccines10.1007/s40588-021-00162-y ↗
9. COVID-19 vaccines: Rapid development, implications, challenges and future prospects10.1007/s13577-021-00512-4 ↗
11. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness10.1038/s41586-020-2622-0 ↗
12. An overview of vaccine development for COVID-1910.4155/tde-2020-0129 ↗
13. Frontiers in the COVID-19 vaccines development10.1186/s40164-020-00180-4 ↗
14. SARS-CoV-2 and the use of chloroquine as an antiviral treatment10.3389/fmed.2020.00184 ↗
15. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease10.1080/07391102.2020.1784291 ↗
16. Repurposing therapeutic agents against SARS-CoV-2 infection: Most promising and neoteric progress10.1080/14787210.2021.1864327 ↗
17. Hydroxychloroquine for the prevention of covid-19—Searching for evidence10.1056/nejme2020388 ↗
18. Repurposing anti-cancer drugs for COVID-19 treatment10.2147/dddt.s282252 ↗
19. Detection of a SARS-CoV-2 variant of concern in South Africa10.1038/s41586-021-03402-9 ↗
20. SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients10.1002/jmv.27066 ↗
21. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies10.1080/14760584.2021.1903879 ↗
22. Rethinking environmental contamination and fomite transmission of SARS-CoV-2 in the healthcare10.1016/j.jinf.2020.08.041 ↗
23. An updated min-review on environmental route of the SARS-CoV-2 transmission10.1016/j.ecoenv.2020.111015 ↗
24. A nanomechanical study on deciphering the stickiness of SARS-CoV-2 on inanimate surfaces10.1021/acsami.0c16800 ↗
25. Transmission of SARS-CoV-2: A review of viral, host, and environmental factors10.7326/m20-5008 ↗
26. Persistence of SARS-CoV-2 in the environment and COVID-19 transmission risk from environmental matrices and surfaces10.1016/j.envpol.2020.115010 ↗
27. Indoor versus outdoor transmission of SARS-COV-2: Environmental factors in virus spread and underestimated sources of risk10.1007/s41207-021-00243-w ↗
28. Risk factors and on-site simulation of environmental transmission of SARS-CoV-2 in the largest wholesale market of Beijing, China10.1016/j.scitotenv.2021.146040 ↗
29. Current understanding of the influence of environmental factors on SARS-CoV-2 transmission, persistence, and infectivity10.1007/s11356-020-12165-1 ↗
30. The inactivation mechanism of chemical disinfection against SARS-CoV-2: From MD and DFT perspectives10.1039/d0ra06730j ↗
31. Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials10.1080/22221751.2021.1872354 ↗
32. SARS-CoV-2 is rapidly inactivated at high temperature10.1007/s10311-021-01187-x ↗
33. SARS-CoV-2 inactivation by ozonated water: A preliminary alternative for environmental disinfection10.1080/01919512.2020.1842998 ↗
34. Inactivation of SARS-CoV-2 by gamma irradiation10.4103/ijmr.IJMR_2789_20 ↗
35. SARS-CoV-2 survival on surfaces and the effect of UV-C light10.3390/v13030408 ↗
36. The effect of heat-treatment on SARS-CoV-2 viability and detection10.1016/j.jviromet.2021.114087 ↗
37. Future antiviral polymers by plasma processing10.1016/j.progpolymsci.2021.101410 ↗
38. A meaningful attempt: Applying dielectric barrier discharge plasma to induce apoptosis of MDA-MB-231 cells via regulating HIF-1α/VEGFA expression10.1016/j.surfcoat.2020.126293 ↗
39. Study on inactivation effects and regeneration inhibition mechanism of atmospheric-pressure helium plasma jet on Acinetobacter baumannii biofilm10.1109/tps.2020.3042809 ↗
40. Immediate intervention effect of dielectric barrier discharge on acute inflammation in rabbit’s ear wound10.1063/1.5139953 ↗
41. Current status on the development of pseudoviruses for enveloped viruses10.1002/rmv.1963 ↗
42. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-1910.1038/s41401-020-0485-4 ↗
43. Characteristics of SARS-CoV-2 and COVID-1910.1038/s41579-020-00459-7 ↗
44. Molecular architecture of the SARS-CoV-2 virus10.1016/j.cell.2020.09.018 ↗
45. Structure of the RNA-dependent RNA polymerase from COVID-19 virus10.1126/science.abb7498 ↗
46. Structural basis for RNA replication by the SARS-CoV-2 polymerase10.1016/j.cell.2020.05.034 ↗
47. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors10.1038/s41586-020-2223-y ↗
48. Cold atmospheric plasma: A powerful tool for modern medicine10.3390/ijms21082932 ↗
49. Dose dependent selectivity and response of different types of mammalian cells to surface dielectric barrier discharge (SDBD) plasma10.1002/ppap.201400134 ↗
50. Dose- and time-dependent cellular effects of cold atmospheric pressure plasma evaluated in 3D skin models10.1159/000450889 ↗
51. Electrical and spectral property of cold arc plasma at atmospheric pressure10.1017/s0022377812000463 ↗
52. Temporal and spatial resolved optical emission behaviors of a cold atmospheric pressure plasma jet10.1063/1.3239512 ↗
53. Enhancement propagation of protocorms in orchid (Cymbidium tracyanum L. Castle) by cold atmospheric pressure air plasma jet10.1007/s11090-020-10148-1 ↗
54. Development and characterization of a multi-electrode cold atmospheric pressure DBD plasma jet aiming plasma application10.1039/c6ja00419a ↗
55. Cold atmospheric plasma: A new strategy based primarily on oxidative stress for osteosarcoma therapy10.3390/jcm10040893 ↗
56. Mechanism of virus inactivation by cold atmospheric-pressure plasma and plasma-activated water10.1128/AEM.00726-18 ↗
57. Cold plasma, a new hope in the field of virus inactivation10.1016/j.tibtech.2020.04.003 ↗
58. Crucial roles of reactive chemical species in modification of respiratory syncytial virus by nitrogen gas plasma10.1016/j.msec.2017.02.007 ↗
59. Nitrogen gas plasma generated by a static induction thyristor as a pulsed power supply inactivates adenovirus10.1371/journal.pone.0157922 ↗
60. Helium low temperature plasma induced HepG2 cells autophagy through ROS-mediated PI3K/AKT/mTOR/P70s6k signaling pathway10.1063/1.5116292 ↗
61. Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection10.1016/j.cej.2020.127742 ↗
62. Decontamination of food packages from SARS-CoV-2 RNA with a cold plasma-assisted system10.3390/app11094177 ↗
63. Cold atmospheric plasma inactivation of aerosolized microdroplets containing bacteria and purified SARS-CoV-2 RNA to contrast airborne indoor transmission10.1002/ppap.202000154 ↗